Stockscreener 앱 받기
1.01
2.63%
0.0259
전일 마감가:
$0.9841
열려 있는:
$0.99
하루 거래량:
289.95K
Relative Volume:
4.71
시가총액:
$31.88M
수익:
$8.38M
순이익/손실:
$-27.19M
주가수익비율:
-
EPS:
-
순현금흐름:
$-13.59M
1주 성능:
-4.72%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$0.98
$1.0124
1주일 범위
$0.8531
$1.0698
52주 변동 폭
$0.8531
$1.36
Opus Genetics Inc Stock (IRD) Company Profile
명칭
Opus Genetics Inc
전화
248-681-9815
주소
37000 GRAND RIVER AVE., FARMINGTON HILLS
IRD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| IRD | 1.01 | 31.88M | 8.38M | -27.19M | -13.59M | 0.00 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Opus Genetics Inc 주식(IRD)의 최신 뉴스
Opus Genetics Inc CEO George Magrath Purchases 100,000 Shares - GuruFocus.com
FY2024 EPS Estimates for Opus Genetics Cut by HC Wainwright - Defense World
Opus Genetics Inc (IRD) Quarterly 10-Q Report - Quartz
Opus Genetics reinstated with a Buy at H.C. Wainwright - Yahoo Finance
IRD stock touches 52-week low at $1.07 amid market challenges - Investing.com India
Opus Genetics (IRD) Stock Chart and Price History 2024 - MarketBeat
Wainwright sets stock target on Opus Genetics, cites 2025 catalysts By Investing.com - Investing.com UK
Opus Genetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
Opus Genetics Reports $7.5 Million Net Loss in Third Quarter - Vision Monday
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics - Lelezard
Ocuphire Pharma Acquires Opus Genetics - Marketscreener.com
North Carolina gains public company with merger - The Business Journals
Ocuphire buys Opus Genetics, grows gene therapy pipeline - The Pharma Letter
Ocuphire Pharma Announces Acquisition of Opus Genetics - Vision Monday
Ocuphire Shares Rise After Extended US Patent For Nyxol Eye Drops Secured - Marketscreener.com
Ocuphire Pharma Merges with Opus Genetics, Renamed Opus Genetics - Yahoo Finance
Ophthalmic Biopharmaceutical Ocuphire Pharma Shifts Focus To Gene Therapy Through Opus Genetics Stock Deal - AOL
Ocuphire and Opus Genetics merge to develop IRD gene therapy - Yahoo Finance
Ademi LLP Investigates Whether Ocuphire Pharma, Inc. Is Breaching Its Duties to Its Public Shareholders - Business Wire
AAO 2024: Epimacular membranes and metamorphopsia - Ophthalmology Times
Ocuphire Pharma acquires Opus Genetics in all-stock deal By Investing.com - Investing.com Australia
Around the Helix: Cell and Gene Therapy Company Updates – October 23, 2024 - CGTLive™
Wilson Sonsini Advises Opus Genetics on IP Matters Related to Acquisition by Ocuphire Pharma - Wilson Sonsini
Ocuphire Pharma acquires Opus Genetics in all-stock deal - Investing.com
Ocuphire Pharma acquires Opus Genetics - Seeking Alpha
Derrick D. Rowe - Wilson Sonsini
News in Cell and Gene Therapy for Rare Cancer Day 2024 - CGTLive™
EyeCon 2024: Taking a multidisciplinary approach to diabetic eye care - Optometry Times
Boehringer Ingelheim to advance SZN-413 for retinal diseases - BioWorld Online
EURETINA 2024: Aleksandra Rachitskaya, MD, FASRS, and the Vit-Buckle Society come to Barcelona - Ophthalmology Times Europe
VEW 2024: Touring the retina with Dr. Steven Ferrucci - Optometry Times
Study: 100x improvement in sight detected after gene therapy trial - Modern Retina
Latest advances in X-linked retinitis pigmentosa: Optimizing diagnosis and developments in gene therapy - Ophthalmology Times
This Week in Ophthalmology: Week of August 18, 2024 - Ophthalmology Times
Opus Genetics Receives Rare Pediatric Disease Designation From the FDA for Ocular Gene Therapy - Vision Monday
Ocuphire Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
William Chou, MD, on Expanding Frontotemporal Dementia Gene Therapy to Both GRN and C9orf72 Mutations - CGTLive™
PHOTON Results and Their Relation to DME Patients in Your Practice - Ophthalmology Times Europe
ASRS 2024: A novel approach to myopic traction maculopathy - Ophthalmology Times Europe
ASRS 2024: Diabetic retinopathy lesions and assessing disease severity over time - Ophthalmology Times Europe
Layoff Tracker: 23andMe to Lay Off 40% of Employees - BioSpace
Vertex’s Diabetes Cell Therapy on Track to Meet Endpoint of Eliminating Severe Hypoglycemic Events - CGTLive™
Gene Therapy Improves Body Composition in Mice Models of Obesity Alone and After Semaglutide Withdrawal - CGTLive™
Salvador Rico, MD, PhD, on Developing Gene Regulation Therapy for Dravet Syndrome - CGTLive™
Leigh Ramos-Platt, MD, on Sharing Experience With Gene Therapy Administration - CGTLive™
Around the Helix: Cell and Gene Therapy Company Updates – June 19, 2024 - CGTLive™
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility - CGTLive™
Around the Helix: Cell and Gene Therapy Company Updates – June 12, 2024 - CGTLive™
Department of HealthAbu Dhabi and Opus Genetics Announce Collaboration to Advance Ground-Breaking Gene Therapy Research for Inherited Retinal Diseases - PR Newswire
Intellia’s Phase 3 Clinical Trial for CRISPR-Based Gene Therapy Enrolls First Patient - CGTLive™
Opus Genetics Inc (IRD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
2.08%
자본화:
|
볼륨(24시간):